Skip to search formSkip to main contentSkip to account menu

Buprenorphine / Naloxone

Known as: Buprenorphine-Naloxone Drug Combination, Buprenorphine-Naloxone, Buprenorphine Naloxone Combination 
A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESIC with naloxone, a NARCOTIC ANTAGONIST to reduce the potential for… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (2)

Analgesics, OpioidNarcotic Antagonists
BuprenorphineBuprenorphine 2 MG / Naloxone 0.5 MG Sublingual TabletBuprenorphine 2.1 MG / Naloxone 0.3 MG Buccal FilmIn Blood

Narrower (1)

Suboxone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment
BackgroundArtemisinin resistance is a major threat to current efforts to eliminate Plasmodium falciparum malaria which rely… 
Review
2014
Review
2014
Opioid substitution treatment in New Zealand: a 40 year perspective.
We provide an overview of the history and philosophy of the treatment for opioid dependence, which has been dominated by… 
Review
2014
Review
2014
Novel anti-malarial combinations and their toxicity
Artemisinin combination therapy for the treatment of uncomplicated malaria includes artemether plus lumefantrine, artesunate plus… 
2014
2014
A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria
BackgroundSickle cell disease (SCD) is a genetic disorder common in malaria endemic areas. In endemic areas, malaria is a major… 
2013
2013
Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs.
Malaria continues to be a difficult disease to eradicate largely because of the widespread populations it affects and the… 
Review
2013
Review
2013
Clinician beliefs and attitudes about buprenorphine/naloxone diversion.
BACKGROUND AND OBJECTIVES Concern about diversion of buprenorphine/naloxone (B/N) in the United States may affect prescribing… 
2011
2011
The Cost of Integrated HIV Care and Buprenorphine/Naloxone Treatment: Results of a Cross-Site Evaluation
Background:Implementing integrated HIV and buprenorphine/naloxone treatment requires cost estimates to plan and obtain funding… 
2009
2009
Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach
Opioid analgesics are known to impact on the central nervous system (CNS). These CNS side effects, such as dizziness and… 
1986
1986
Radioimmunoassay of Buprenorphine with Iodine Label: Analysis of Buprenorphine and Metabolites in Human Plasma
Quantitative analysis of potent opiate drugs in plasma by radioimmunoassay is potentially inaccurate because of the occurence of… 
1977
1977
Buprenorphine hydrochloride: Determination of analgesic potency
  • A. Dobkin
  • Canadian Anaesthetists' Society journal
  • 1977
  • Corpus ID: 24360279
Summary and ConclusionsAn open evaluation of relief from severe pain following major abdominal operations was carried out on at… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)